RESUMEN
BACKGROUND: Asthma is a common chronic respiratory disease leading to morbidity, mortality and impaired quality of life worldwide. Information on asthma prevalence in the Middle East is fragmented and relatively out-dated. The SNAPSHOT program was conducted to obtain updated information. METHODS: SNAPSHOT is a cross-sectional epidemiological program carried out in five Middle Eastern countries (Egypt, Turkey, Kuwait, Saudi Arabia, and the United Arab Emirates, the latter three grouped into a Gulf cluster) to collect data on asthma, allergic rhinitis, benign prostatic hyperplasia and bipolar disorder. The survey was carried out by telephone in a random sample of the adult general population with quotas defined according to country demographics. The analysis presented in this paper focuses on asthma. Subjects were screened for asthma based on criteria from the global Asthma Insights and Reality studies. Current prevalence (last 12 months) was estimated. Multivariate logistic regression analyses were used to investigate risk factors related to asthma and the association with allergic rhinitis and other co-morbidities. Quality of life was assessed using the three-level EQ-5D questionnaire. RESULTS: 2124 out of the 33,486 subjects enrolled in the SNAPSHOT program fulfilled the criteria for asthma. The adjusted prevalence of asthma ranged from 4.4% [95% CI: 4.0-4.8%] in Turkey, to 6.7% [95% CI: 6.2-7.2%] in Egypt and 7.6% [95% CI: 7.1-8.0%] in the Gulf cluster. Prevalence was higher (p < 0.0001) in women than men and increased with age (p < 0.0001). Co-morbidities occurred more frequently in asthma subjects compared to the non-asthma population (38% vs. 15% p < 0.0001). Subjects with asthma reported a lower (p < 0.0001) EQ-VAS score (68.2 ± 22.9) compared to the general population (78.1 ± 17.5). The risk factors associated with asthma were age, gender, country, and certain co-morbidities, namely respiratory, cardiovascular, gastrointestinal, nervous, and neurological diseases. CONCLUSION: The observed adjusted prevalence of asthma in the Middle East ranges from 4.4% to 7.6%, which is comparatively lower than the reported prevalence in Europe and North America. Asthma has a negative impact on quality of life, and is associated with high levels of co-morbid diseases, indicating a need for physicians to check for co-morbidities and ensure they are managed correctly in all asthma patients.
Asunto(s)
Asma , Enfermedades no Transmisibles/epidemiología , Calidad de Vida , Adulto , Factores de Edad , Asma/epidemiología , Asma/fisiopatología , Asma/psicología , Asma/terapia , Comorbilidad , Estudios Transversales , Manejo de la Enfermedad , Femenino , Humanos , Masculino , Persona de Mediana Edad , Medio Oriente/epidemiología , Evaluación de Necesidades , Prevalencia , Factores Sexuales , Encuestas y CuestionariosRESUMEN
INTRODUCTION: In recent decades, waterpipe use has gained popularity, notably in the Middle East and North Africa (MENA) region. This study describes waterpipe use and characteristics of waterpipe users among the general population of the MENA region. METHODS: This study was a sub-analysis of the BREATHE study, a cross-sectional survey of chronic obstructive respiratory disease conducted in the general population of 11 countries of the MENA region. The study population consisted of subjects aged ≥40 years who completed the screening questionnaire and who reported waterpipe use (alone or with cigarettes). This questionnaire collected data on demographics, self-reported respiratory symptoms (breathlessness and productive cough), smoking habits (cigarettes or waterpipe) and diagnosis of chronic obstructive respiratory disease, chronic bronchitis or emphysema. RESULTS: Of the 62 086 subjects screened in the BREATHE study, waterpipe use was reported by 2173 subjects (3.5% [95% CI: 3.4%-3.6%]), of whom 934 subjects (43.0%) smoked both waterpipes and cigarettes. The majority of waterpipe users were men (82%) and aged from 40 to 49 years (53.7%). Over 90% of users smoked their waterpipe for ≥1 hour per day. Waterpipe use was associated with an increased risk of productive cough (odds ratio [OR]: 1.49), breathlessness (OR: 1.33), and chronic bronchitis (OR: 1.43), independently of the risk associated with cigarette smoking. In subjects using waterpipe alone (N = 1239), breathlessness was the most frequently self-reported symptom (11.3%), followed by productive cough (6.0%) and chronic bronchitis (2.2%). CONCLUSIONS: Waterpipe smoking in the region is widespread and is associated with an increased risk of respiratory pathology independently of cigarette smoking. IMPLICATIONS: This large general population study reports an elevated risk of respiratory disease associated with waterpipe use independently of cigarette smoking; this finding emphasizes the need for public health policies to curtail the growing spread of waterpipe use by young people in the MENA region.
Asunto(s)
Enfermedad Pulmonar Obstructiva Crónica/epidemiología , Fumar en Pipa de Agua/epidemiología , Adulto , África del Norte/epidemiología , Factores de Edad , Estudios Transversales , Femenino , Humanos , Masculino , Persona de Mediana Edad , Medio Oriente/epidemiología , Enfermedad Pulmonar Obstructiva Crónica/etiología , Factores Sexuales , Encuestas y Cuestionarios , Fumar en Pipa de Agua/efectos adversosRESUMEN
OBJECTIVES: To present data on the prevalence of benign prostatic hyperplasia (BPH) in five Middle Eastern countries (Egypt, Turkey, Kuwait, Saudi Arabia, and the United Arab Emirates; the latter three forming a Gulf cluster). SUBJECTS AND METHODS: The SNAPSHOT programme was a multi-country, cross-sectional epidemiological survey conducted by telephone in a random sample of the adult general population. Subjects were considered to have BPH if they fulfilled the screening criteria, based on diagnosis, symptoms, and treatments received in the past 12 months. Current prevalence (last 12 months) was estimated. Association with co-morbidities was investigated via multivariate logistic regressions. Quality of life (QoL) was assessed using the three-level EuroQol five-dimensions questionnaire (EQ-5D-3 L). RESULTS: In total, 5034 of 33,486 subjects enrolled in the SNAPSHOT programme were men aged ≥50 years. In all, 998 of these men fulfilled the BPH screening criteria. The overall prevalence of BPH ranged from 13.84% (95% confidence interval[CI] 12.3-15.4%) in Turkey, to 23.76% (95% CI 21.8-25.6%) in Egypt, and 23.79% (95% CI 21.2-26.3%) in the Gulf cluster. Co-morbidities occurred more frequently in men with BPH compared to the non-BPH population (57% vs 31%; P < 0.001). Principal co-morbidities associated with BPH were cardiovascular, renal, and diabetes mellitus (P < 0.001). The men with BPH reported significantly reduced QoL, with lower EQ-5D-3 L utility values (0.8) compared to the male general population (0.9) aged ≥50 years (P < 0.001). CONCLUSION: The prevalence of BPH in these five Middle Eastern countries ranges from 13.84% to 23.79%. BPH has a negative impact on QoL and is associated with high levels of co-morbid diseases, indicating a need to better understand the management of the disease to reduce the impact on healthcare systems.
RESUMEN
OBJECTIVE: To identify the factors associated with regular cervical screening (CS) in the French female population. METHODS: Face-to-face interviews with 5354 randomly selected French women were carried out in this population-based, observational, cross-sectional study. The variables found significant by univariate analysis were entered in a stepwise analysis. A multivariate logistic model constructed with these variables permitted to identify which were significantly related to women undergoing regular CS. RESULTS: A significant relationship was found between regular CS and previous screening for HIV infection, being professionally active, fear of cervical cancer, level of education, and having had a gynecologic check-up in the past 5 years. CONCLUSION: Since the study sample was known to be representative of the female adult population, most of our observations may have important public health implications in France, where information on HPV infection and its possible consequences need to be improved.
Asunto(s)
Conocimientos, Actitudes y Práctica en Salud , Cooperación del Paciente/estadística & datos numéricos , Neoplasias del Cuello Uterino/prevención & control , Frotis Vaginal/estadística & datos numéricos , Adolescente , Adulto , Anciano , Estudios Transversales , Femenino , Francia , Conductas Relacionadas con la Salud , Humanos , Persona de Mediana EdadRESUMEN
INTRODUCTION: The human papillomavirus (HPV) is the most common cause of sexually transmitted infections worldwide, and its prevalence is highest among young women aged 17-25 years. It is the principal risk factor for cervical cancer. Systematic vaccination of adolescent girls should significantly reduce the incidence of this disease and its related mortality. AIM: One of the objectives of the Enjeux study, a population-based survey, was to identify the place of young girls within the French health care system to help assess the optimal conditions for implementing anti-HPV vaccination. METHODS: Data came from 5354 interviews of women aged 18-70 years, 320 of whom provided information about daughters aged 11-14 years and 406 about daughters aged 15-17 years. Among the latter, 318 were also interviewed and 294 completed a self-administered questionnaire. RESULTS: The results showed that sexual activity was reported by approximately one third of the girls aged 15-17 years. At-risk behaviors in these girls included insufficient contraception (only 51% use condoms). Data on the medical management of the population of 11-17 year-old girls indicate that they have access to - and are integrated into - the health care system, with frequent medical visits. They see the general practitioner (GP) most frequently, followed by the school doctor. The frequency of general practice visits is similar in both age groups; more than 50% of the girls visit their GP more than twice a year. Vaccination is a frequent reason for these visits; gynecologic reasons are less frequent. CONCLUSION: The results of this survey underline the central place of the GP in the health management of young girls aged 11 to 17 years.
Asunto(s)
Accesibilidad a los Servicios de Salud/estadística & datos numéricos , Infecciones por Papillomavirus/prevención & control , Adolescente , Niño , Estudios Transversales , Femenino , Francia , HumanosRESUMEN
BACKGROUND: COPD affects millions of people worldwide. Poor treatment adherence contributes to increased symptom severity, morbidity and mortality. This study was designed to investigate adherence to COPD treatment in Turkey and Saudi Arabia. METHODS: An observational, cross-sectional study in adult COPD patients in Turkey and Saudi Arabia. Through physician-led interviews, data were collected on sociodemographics and disease history, including the impact of COPD on health status using the COPD Assessment Test (CAT); quality of life, using the EuroQol Five-Dimension questionnaire (EQ-5D); and anxiety and depression using the Hospital Anxiety and Depression Scale (HADS). Treatment adherence was measured using the 8-item Morisky Medication Adherence Scale (MMAS-8). Multivariate logistic regression analysis examined the predictors of non-adherence and the impact of adherence on symptom severity. RESULTS: Four hundred and five COPD patients participated: 199 in Turkey and 206 in Saudi Arabia. Overall, 49.2% reported low adherence (MMAS-8 <6). Of those, 74.7% reported high disease impact (CAT >15) compared to 58.4% reporting medium/high adherence (p=0.0008). Patients with low adherence reported a lower mean 3-level EQ-5D utility value (0.54±0.35) compared to those with medium/high adherence (0.64±0.30; p<0.0001). Depression with HADS score 8-10 or >10 was associated with lower adherence (OR 2.50 [95% CI: 1.43-4.39] and 2.43 [95% CI: 1.39-4.25], respectively; p=0.0008). Being a high school/college graduate was associated with better adherence compared with no high school (OR 0.57 [95% CI: 0.33-0.98] and 0.38 [95% CI: 0.15-1.00], respectively; p=0.0310). After adjusting for age, gender, and country, a significant association between treatment adherence (MMAS-8 score ≥6) and lower disease impact (CAT ≤15) was observed (OR 0.56 [95% CI: 0.33-0.95]; p=0.0314). CONCLUSION: Adherence to COPD treatment is poor in Turkey and Saudi Arabia. Non-adherence to treatment is associated with higher disease impact and reduced quality of life. Depression, age, and level of education were independent determinants of adherence.
Asunto(s)
Cumplimiento de la Medicación , Enfermedad Pulmonar Obstructiva Crónica/tratamiento farmacológico , Adulto , Factores de Edad , Distribución de Chi-Cuadrado , Estudios Transversales , Depresión/psicología , Escolaridad , Conocimientos, Actitudes y Práctica en Salud , Estado de Salud , Humanos , Entrevistas como Asunto , Modelos Logísticos , Salud Mental , Persona de Mediana Edad , Análisis Multivariante , Oportunidad Relativa , Enfermedad Pulmonar Obstructiva Crónica/diagnóstico , Enfermedad Pulmonar Obstructiva Crónica/fisiopatología , Enfermedad Pulmonar Obstructiva Crónica/psicología , Calidad de Vida , Factores de Riesgo , Arabia Saudita , Índice de Severidad de la Enfermedad , Encuestas y Cuestionarios , Resultado del Tratamiento , TurquíaRESUMEN
BACKGROUND: Asthma affects millions worldwide resulting in a significant disease burden. However, data on asthma burden from the Middle East is limited. This analysis describes the asthma burden in Egypt, Turkey and a Gulf cluster (Kuwait, Saudi Arabia and United Arab Emirates) as part of the SNAPSHOT program. METHODS: SNAPSHOT was an observational, cross-sectional program carried out by telephone in a random sample of the adult general population of the five above mentioned countries. Quotas were defined per country demographics. Subjects were considered to have asthma if they fulfilled the screening criteria, based on the global Asthma Insights and Reality studies. Data collected included demographics, physician consultations, and asthma control (measured by the Asthma Control Test; ACT). Quality of life was assessed using the EuroQol Five-Dimension questionnaire (EQ-5D); and limitations to daily activities using the modified Sheehan Disability Scale (SDS). RESULTS: 939 subjects answered questions related to asthma burden. Overall, 367 (44.2%) reported uncontrolled asthma (ACT≤19), and reported significantly lower EQ-5D-3L utility values (0.6⯱â¯0.4) and EQ-VAS scores (60.7⯱â¯24.2) compared to controlled subjects (0.8⯱â¯0.3 and 75.3⯱â¯19.8 respectively) (pâ¯<â¯0.0001). A significantly higher proportion with uncontrolled asthma also reported experiencing impact on activities of daily living compared to subjects with controlled asthma (pâ¯<â¯0.0001). Overall, 355 (37.8%) asthma subjects were followed by a physician. However, most visits were unscheduled (695;78.0%). CONCLUSION: Uncontrolled asthma imposes a significant burden in these Middle Eastern countries resulting in increased frequency of healthcare use, lower quality of life, and a higher impact on daily life compared to controlled asthma.
Asunto(s)
Actividades Cotidianas/psicología , Asma/epidemiología , Calidad de Vida/psicología , Adulto , Anciano , Asma/psicología , Estudios Transversales , Egipto/epidemiología , Femenino , Humanos , Kuwait/epidemiología , Masculino , Persona de Mediana Edad , Arabia Saudita/epidemiología , Índice de Severidad de la Enfermedad , Encuestas y Cuestionarios , Turquía/epidemiología , Emiratos Árabes Unidos/epidemiología , Adulto JovenRESUMEN
BACKGROUND: The SNAPSHOT program provides current data on the allergic rhinitis burden in the adult general population of five Middle Eastern countries (Egypt, Turkey, Kuwait, Saudi Arabia and the United Arab Emirates, the latter three grouped into a Gulf cluster). METHODS: A multi-country, cross-sectional, epidemiological program conducted by telephone in a random sample of the adult general population; quotas were defined per country demographics. Subjects were screened for allergic rhinitis using the Score For Allergic Rhinitis questionnaire. Current prevalence (last 12 months) was estimated. Disease severity and control were assessed using the Allergic Rhinitis and its Impact on Asthma classification and Rhinitis Control Assessment Test respectively. Quality of sleep, impact on daily activities and quality of life were measured using the Epworth Sleepiness Scale, Sheehan Disability Scale and EuroQol Five-Dimension questionnaire respectively. Multivariate logistic regression analyses were used to investigate risk factors and co-morbidities. RESULTS: 1808 of 33,486 subjects enrolled in the SNAPSHOT program fulfilled the case definition for allergic rhinitis. Prevalence was 3.6% [95% CI 3.2-4.0%] in Egypt, 6.4% [95% CI 5.9-6.9%] in Turkey and 6.4% [95% CI 6.0-6.9%] in the Gulf cluster. Risk factors identified were country, co-morbid asthma and income. Subjects with allergic rhinitis reported a significantly lower quality of life compared to the general population (p < 0.0001). Overall, 55% of allergic rhinitis subjects were moderate/severe and 33% were uncontrolled. Both these groups reported impaired quality of life and quality of sleep and increased impairment of daily activities compared to mild/well-controlled subjects (p < 0.0001). CONCLUSIONS: Although the observed prevalence of allergic rhinitis in these Middle Eastern countries is low compared to western countries, its burden is considerable. Allergic rhinitis in general, and specifically uncontrolled and severe disease, results in a negative impact on quality of life, quality of sleep and daily activities.
RESUMEN
BACKGROUND: The public health burden of osteoporosis is high, principally because of increased risk of fractures and associated morbidity, handicap and mortality. Osteoporotic fracture prevention is therefore an important public health goal. General practitioners (GPs) play a key role in the management of osteoporosis, both in ensuring timely diagnosis and in providing treatment. Little information is available on standards of care for postmenopausal women with osteoporosis in general practice. OBJECTIVES: The primary objective of this study was to describe risk factors and treatment in postmenopausal women with osteoporosis. Secondary objectives were to evaluate treatment compliance and to assess the impact of osteoporosis on quality of life. METHODS: This observational, cross-sectional, pharmacoepidemiological study was performed in a primary-care setting in France. A random sample of GPs recruited postmenopausal women with a diagnosis of osteoporosis who had been followed by the investigator for at least 2 years. At inclusion, investigators completed a questionnaire providing information on patient age, osteoporosis duration, risk factors and treatment history. The first three patients recruited by each investigator completed a questionnaire providing information on sociodemographic features, osteoporosis treatments and quality of life. Treatment compliance was quantified using the Test d'Evaluation de l'Observance and quality of life evaluated using the 12-item Short Form Health Survey (SF-12). RESULTS: Overall, 389 physicians included 3,097 patients, of whom 1,053 completed the patient questionnaire. Risk factors for osteoporotic fracture were identified in 2,148 patients (69.4%), most frequently personal or maternal antecedents of osteoporotic fracture and a low body mass index. Of these, 946 (44.0%) presented more than one risk factor. At the time of diagnosis, 629 patients (59.7%) presented fractures, which involved the vertebrae in 51.7% of cases, the wrist in 40.5% and the hip in 5.4%. Older patients were more likely to have fractures at the time of diagnosis and to have multiple fractures. After diagnosis, at least one new fracture occurred in 201 patients (19.2%). Multivariate logistic regression analysis identified age >70 years, diagnosis at least 10 years previously, diagnosis based on the presence of a fracture, biochemical and haematological evaluation at the time of diagnosis, and a change in osteoporosis treatment in the previous 2 years as being significantly associated with incident fracture risk. At inclusion, 1,019 patients (97.4%) were receiving treatment for osteoporosis, most frequently weekly bisphosphonates (71.6% of treatments). Most patients (81.0%) had been treated for at least 1 year. Treatment compliance was high in 61% of patients and low in <5%. Patient variables associated with high compliance were being retired, prescription of bisphosphonates and, among the bisphosphonate users, prescription of weekly formulations. SF-12 quality-of-life scores were low, ranging from 38.6 (energy/vitality) to 65.1 (social functioning) out of a possible maximum score of 100. Baseline variables associated with SF-12 physical component summary scores included age, height loss since menopause, diagnosis following a fracture, fracture incidence since diagnosis, time since diagnosis and treatment with bisphosphonates. CONCLUSIONS: In this study of postmenopausal osteoporosis in the French primary healthcare setting, many women with osteoporosis were diagnosed following a fracture. Although most were treated with bone-consolidating drugs, compliance was suboptimal in a significant minority. Osteoporotic fracture was associated with reduced quality of life.
Asunto(s)
Osteoporosis Posmenopáusica/diagnóstico , Osteoporosis Posmenopáusica/tratamiento farmacológico , Atención Primaria de Salud/métodos , Adulto , Anciano , Anciano de 80 o más Años , Envejecimiento , Estudios Transversales , Femenino , Estudios de Seguimiento , Fracturas Óseas/epidemiología , Fracturas Óseas/prevención & control , Francia/epidemiología , Humanos , Persona de Mediana Edad , Osteoporosis Posmenopáusica/epidemiología , Cooperación del Paciente/estadística & datos numéricos , Farmacoepidemiología/métodos , Farmacoepidemiología/estadística & datos numéricos , Atención Primaria de Salud/estadística & datos numéricos , Calidad de Vida , Factores de RiesgoRESUMEN
Quality of life is impaired in patients with epilepsy and can be improved by effective therapy. Randomised clinical trials have shown that lamotrigine treatment is associated with improved quality of life. However, little information is available on quality of life or treatment effects in patients with epilepsy in the general population. The objective of this study was to estimate the impact of lamotrigine on quality of life in a naturalistic treatment setting. The study included adult patients with epilepsy in whom lamotrigine therapy was initiated. Each subject completed the Quality of Life in Epilepsy Inventory (QOLIE)-31 quality of life questionnaire at inclusion and at a follow-up visit in the next 4 months. Demographic information and medical history were provided by the investigator. These were evaluated as potential determinants of change in quality of life using logistic regression. Three hundred and forty-one patients were evaluated, 192 starting lamotrigine in combination with another drug, 90 as a first-line monotherapy, 45 as a switch from another drug and 14 as a reduction to monotherapy from a previous combination. Baseline scores on the QOLIE-31 ranged from 53.8 in the combination group to 69.5 in the first-line group. 34.6% of patients were considered to be responders, with no significant differences between treatment regimen. Most improvement was seen for the energy-fatigue and medication effects subscales and, for the first-line group, seizure worry. Seizure type was the only determinant of improvement of quality of life identified. In conclusion, lamotrigine treatment is associated with improved quality of life, regardless of treatment regimen.
Asunto(s)
Anticonvulsivantes/uso terapéutico , Epilepsia/tratamiento farmacológico , Calidad de Vida , Triazinas/uso terapéutico , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Anticonvulsivantes/administración & dosificación , Quimioterapia Combinada , Epilepsia/psicología , Femenino , Humanos , Lamotrigina , Modelos Logísticos , Masculino , Persona de Mediana Edad , Observación , Estudios Prospectivos , Encuestas y Cuestionarios , Triazinas/administración & dosificaciónRESUMEN
BACKGROUND: Allergic rhinitis (AR) is common and has been shown to impair social life and sleep. Patients with severe symptoms may have more sleep disturbances than those with a mild form of the disease, but this has never been assessed using a validated tool. The objective of our study was to assess, in patients with AR, whether duration and severity of AR are associated with sleep impairment. METHODS: A nationwide controlled cross-sectional epidemiological study was carried out. A representative sample of 260 French ear, nose, and throat and allergy specialists enrolled 591 patients with AR of at least 1 year's duration. Sleep disorders, sleep quality, and AR were assessed using validated tools (Sleep Disorders Questionnaire, Epworth Sleepiness Scale, and Score for Allergic Rhinitis). The severity of AR was assessed using the Allergic Rhinitis and its Impact on Asthma classification. RESULTS: All dimensions of sleep were impaired by AR, particularly by the severe type. Sleep was significantly more impaired in patients with severe AR than in those with the mild type. The duration of AR (intermittent or persistent) had no effect on sleep. CONCLUSION: These data underline the close relationship between AR and sleep and highlight the need for clinicians, particularly general practitioners, to be attentive in this respect.
Asunto(s)
Rinitis Alérgica Perenne/complicaciones , Trastornos del Sueño-Vigilia/etiología , Adulto , Consumo de Bebidas Alcohólicas/epidemiología , Ansiedad/epidemiología , Asma/epidemiología , Estudios de Casos y Controles , Estudios Transversales , Depresión/epidemiología , Fatiga/epidemiología , Femenino , Francia/epidemiología , Cefalea/epidemiología , Humanos , Hipnóticos y Sedantes/administración & dosificación , Masculino , Trastornos de la Memoria/epidemiología , Rinitis Alérgica Perenne/epidemiología , Índice de Severidad de la Enfermedad , Factores Sexuales , Conducta Sexual , Trastornos del Sueño-Vigilia/epidemiología , Ronquido/epidemiología , Encuestas y CuestionariosRESUMEN
INTRODUCTION: Migraine is a prevalent neurological disorder that can be alleviated by specific treatment for acute headaches, in particular, the triptans, including naratriptan. France has developed official guidelines for the use of triptans as part of migraine management. This pharmacoepidemiological study sought to evaluate how naratriptan is prescribed and used in community medicine in France. METHODS: The protocol called for general practitioners to be randomly selected from a list of all physicians in France and for each to include two patients with migraine. Data came from questionnaires completed by the physician and by the patient (including HIT-6 and QVM to assess headache impact and quality of life) as well as a patient diary. RESULTS: In all, 2530 physicians included 3863 patients: 54.3% were treated with naratriptan, 22.4% with another triptan and 23.3% with a non-triptan medication. Of the patients receiving naratriptran, 82.3% were women. Migraine impact was greater and quality of life worse in the patients receiving triptans than those treated with other medications (p<0.0001). Naratriptan was prescribed as second-line treatment following failure of an NSAID in 44.2% of patients taking it; 55.3% of them were prescribed a single dose per headache. Overall, initial treatment was taken right at the beginning of the migraine attack in 70.5% of headaches. DISCUSSION: Data from this cross-sectional study indicate that triptans in general and naratriptan in particular are most often prescribed for patients with the most severe migraines. Consistent with official French guidelines, physicians often recommend taking naratriptan after and only if a NSAID fails to provide relief. Nonetheless, one patient in three starts treatment late, which may significantly reduce the efficacy rate, increase the risk of recurrence and side effects, and prolong the headache. CONCLUSION: Naratriptan is generally prescribed in accordance with official guidelines. Delay in taking medication by around one third of patients probably reduces its efficacy.
Asunto(s)
Trastornos Migrañosos/tratamiento farmacológico , Piperidinas/uso terapéutico , Triptaminas/uso terapéutico , Adulto , Prescripciones de Medicamentos/estadística & datos numéricos , Utilización de Medicamentos/estadística & datos numéricos , Medicina Familiar y Comunitaria , Femenino , Francia , Humanos , Masculino , Encuestas y CuestionariosRESUMEN
Patient-reported outcome, relating to the impact of disease and therapy on the wellbeing of the patient, has become an essential part of medicine, guiding enlightened public health policy and resource attribution. Assessment of patient-reported outcome requires the development of specific and validated instruments, generally questionnaires completed by the patient. In the case of migraine, a number of such specific instruments have been developed to measure severity, associated disability, effects on quality of life and overall impact of headache. In addition, generic quality of life measures have allowed migraine to be compared with other pathologies. For example, using the SF-36 generic health-related quality of life profile, quality of life has been shown to be negatively associated with headache severity, impacted more by migraine headaches than by other forms of episodic headache, and diminished to a similar degree in migraine and in other chronic disorders such as depression. Migraine-specific quality of life measures have also been developed, and these are more sensitive to change than generic measures. An example is the QVM scale that has been used to demonstrate an improvement in quality of life following treatment with a triptan. Moreover, quality of life scores on this measure are inversely related to the economic cost of migraine. Disability associated with migraine can be measured using the MIDAS scale. Disability has been shown to be determined by the frequency and severity of headaches and by the headache syndrome itself, with migraine causing more disability than other forms of episodic headache. The MIDAS scale has been used to develop treatment strategies stratified on the level of disability. The severity of individual headaches can be quantified using the MIGSEV scale. The severity of individual headaches has been shown to be closely associated with overall disability, quality of life and overall healthcare expenditure. Finally, the global impact of headaches is measured using the HIT-6 questionnaire, which discriminates well between different headache types and is again closely related to quality of life. These and other measures of the patient's perception of migraine have allowed an ever more precise picture of this multifacetted disorder to be drawn.
Asunto(s)
Trastornos Migrañosos/diagnóstico , Trastornos Migrañosos/fisiopatología , Percepción/fisiología , Perfil de Impacto de Enfermedad , Evaluación de la Discapacidad , Humanos , Satisfacción del Paciente , Índice de Severidad de la Enfermedad , Encuestas y CuestionariosRESUMEN
Orofacial herpes is a common benign disease suspected to significantly impact the quality of life (QOL) of affected subjects. The objective of this population-based study was to evaluate the annual prevalence of orofacial herpes in France, its epidemiology, and its impact on QOL. Face-to-face home interviews were conducted among a random sample of 10,263 adults. A screening questionnaire identified subjects with a history of orofacial herpes (or cold sore) during the past 12 months; then, subjects with herpes completed another questionnaire to further describe their disorder and its management, and the SF-36 questionnaire to assess their QOL. The annual prevalence of orofacial herpes was 14.8% (95% confidence interval 14.03; 15.47); it was significantly higher in women than in men (P < .001) and decreased with age (P < .001). Among subjects with herpes, only 23% were aware of their disease. Tiredness and emotional stress were the main triggering events. There was no detectable difference between subjects with herpes and controls on SF-36 scores; however, when compared with subjects with 1 to 5 episodes per year, subjects with 6 or more episodes per year had significantly lower QOL scores.
Asunto(s)
Herpes Labial/epidemiología , Calidad de Vida , Adolescente , Adulto , Anciano , Fatiga , Femenino , Francia/epidemiología , Encuestas Epidemiológicas , Herpes Labial/complicaciones , Herpes Labial/psicología , Humanos , Masculino , Persona de Mediana Edad , Prevalencia , Estrés PsicológicoRESUMEN
AIMS: To assess the impact of irritable bowel syndrome (IBS) on patient-reported health-related quality of life (HRQOL). METHODS: Two HRQOL instruments were administered by telephone interviews to a sample of 253 IBS French patients recruited from the general population. IBS was diagnosed according to the Manning, Rome I and Rome II criteria. Patients with organic diseases were excluded from the study. A generic instrument, the Short Form 36 (SF-36), and an IBS disease-specific instrument, the IBSQOL, were used. RESULTS: Patients with IBS had statistically significant (P<0.05) lower scores for all SF-36 QOL domains compared with the general French population. Women (N=192) reported significantly (P<0.05) poorer HRQOL on both the SF-36 and the IBSQOL scores than men (N=61) for all domains except energy on the SF36 and the sleep on the IBSQOL. HRQOL deteriorated with time since onset of IBS symptoms for some domains such as diet. For both instruments, a positive correlation was observed between low scores and intensity of pain and discomfort. IBS patients with a predominance of diarrhea (N=72) exhibited significantly greater impairment of HRQOL in the emotional domain than IBS persons with constipation predominance (N=65) (PAsunto(s)
Síndrome del Colon Irritable/psicología
, Calidad de Vida
, Adolescente
, Adulto
, Anciano
, Anciano de 80 o más Años
, Femenino
, Francia/epidemiología
, Humanos
, Síndrome del Colon Irritable/epidemiología
, Masculino
, Persona de Mediana Edad
, Índice de Severidad de la Enfermedad
, Factores Sexuales
, Encuestas y Cuestionarios
RESUMEN
BACKGROUND: Imported malaria remains an important, but often unrecognised, health problem in Europe. Little information exists on the incidence of imported malaria with respect to exposure. This study aimed to estimate the incidence of malaria in a cohort of travellers with respect to protection measures. METHOD: In all 13,017 participants enrolled in a French general population cohort (SU.VI.MAX cohort) and followed-up over 8 years were investigated. All participants received a retrospective questionnaire about travel to malaria-endemic countries relating to countries visited, duration of stay, use of protection measures and chemoprophylaxis. Malaria cases was confirmed from medical records. RESULTS: Data were obtained for 752 individuals who made 1,393 trips to malaria-endemic areas. This sample was predominantly middle-class and high-risk groups such as migrants were not represented. Mechanical protection was used in 589 trips (42.3%) and chemoprophylaxis in 1,017 trips (73.0%). This was appropriate for the zone in 615 trips (44.0%) and adequate compliance was reported in the case of 497 trips (35.6%). Appropriate chemoprophylaxis and physical protection measures were used in 21.7% of the trips. Six laboratory-confirmed cases of imported malaria yielded an estimated incidence density of 148 cases/month of exposure/10,000 travellers. In five cases, appropriate protection measures had not been taken. CONCLUSION: Appropriate chemoprophylaxis and physical protection measures against malaria infection are used by less than one-quarter of a sample of predominantly middle-class travellers from France to endemic areas. More intense education measures need to be implemented to reduce the risk of imported malaria.
Asunto(s)
Antimaláricos/administración & dosificación , Malaria/epidemiología , Malaria/prevención & control , Control de Mosquitos/métodos , Viaje , Adulto , Ropa de Cama y Ropa Blanca , Quimioprevención , Estudios de Cohortes , Femenino , Francia/epidemiología , Humanos , Incidencia , Mordeduras y Picaduras de Insectos/prevención & control , Insecticidas/farmacología , Masculino , Persona de Mediana Edad , Factores de Riesgo , Encuestas y CuestionariosRESUMEN
OBJECTIVE: To assess the frequency of comorbidities in subjects with COPD and their association with respiratory symptom severity and COPD exacerbations. MATERIALS AND METHODS: This was an analysis of the BREATHE study, a cross-sectional survey of COPD conducted in the general population of eleven countries in the Middle East and North Africa, including Pakistan. The study population consisted of a sample of subjects with COPD for whom the presence of comorbidities was documented. Three questionnaires were used. The screening questionnaire identified subjects who fulfilled an epidemiological case definition of COPD and documented any potential comorbidities; the detailed COPD questionnaire collected data on respiratory symptoms, COPD exacerbations, and comorbidities associated with COPD; the COPD Assessment Test collected data on the impact of respiratory symptoms on well-being and daily life. RESULTS: A total of 2,187 subjects were positively screened for COPD, of whom 1,392 completed the detailed COPD questionnaire. COPD subjects were more likely to report comorbidities (55.2%) than subjects without COPD (39.1%, P<0.0001), most frequently cardiovascular diseases. In subjects who screened positively for COPD, the presence of comorbidities was significantly (P=0.03) associated with a COPD Assessment Test score ≥10 and with antecedents of COPD exacerbations in the previous 6 months (P=0.03). CONCLUSION: Comorbidities are frequent in COPD and associated with more severe respiratory symptoms. This highlights the importance of identification and appropriate management of comorbidities in all subjects with a diagnosis of COPD.
Asunto(s)
Enfermedades Cardiovasculares/epidemiología , Diabetes Mellitus/epidemiología , Enfermedad Pulmonar Obstructiva Crónica , Adulto , África del Norte/epidemiología , Estudios Transversales , Progresión de la Enfermedad , Femenino , Humanos , Masculino , Persona de Mediana Edad , Medio Oriente/epidemiología , Pakistán/epidemiología , Enfermedad Pulmonar Obstructiva Crónica/diagnóstico , Enfermedad Pulmonar Obstructiva Crónica/epidemiología , Pruebas de Función Respiratoria , Índice de Severidad de la Enfermedad , Brote de los SíntomasRESUMEN
BACKGROUND: Occasional cases of acyclovir resistance have been documented in the treatment of herpes simplex virus (HSV) infection. Thirty-eight subjects with acyclovir-resistant infections were identified in an epidemiological surveillance program involving 1811 HSV-infected subjects in France. METHODS: Twenty-three index cases from whom acyclovir-resistant HSV strains had been isolated were compared with 46 control subjects matched for immunological status. Sociodemographic characteristics, features of the acyclovir-resistant HSV episode, history of HSV infection, treatment, outcome, and immunological history were recorded. RESULTS: Twenty-two index case patients presented with immunodepression. Sixty-five percent reported clinically manifest recurrences, compared with 33% of matched control subjects. Significantly more index case patients had used antiviral drugs, and they had used them more often than had control subjects. However, 26.1% of index case patients reported no antiviral exposure in the previous 2 years. Two-thirds of the strains recovered from the index case patients were isolated because of suspicion of clinical resistance to acyclovir. CONCLUSIONS: Clinical treatment resistance is associated with acyclovir-resistant HSV strains, but acyclovir-resistant strains were also isolated from treatment-naive subjects.
Asunto(s)
Aciclovir/farmacología , Antivirales/farmacología , Farmacorresistencia Viral , Simplexvirus/efectos de los fármacos , Adulto , Anciano , Estudios de Casos y Controles , Femenino , Herpes Simple/tratamiento farmacológico , Herpes Simple/virología , Humanos , Masculino , Persona de Mediana Edad , Estudios RetrospectivosRESUMEN
A psychometric evaluation of a French version of the side-effects and life satisfaction inventory (SEALS) was carried out. SEALS was compared to the quality of life in epilepsy-31 questionnaire (QOLIE-31) and a generic, health-related quality-of-life questionnaire, the Nottingham health profile (NHP). The psychometric properties of SEALS, assessed in 190 adult subjects with epilepsy, included: acceptability, test-retest reliability and validity, multitrait analysis including internal consistency and item-to-scale correlations, construct validity using factor analysis and discriminative validity using associations with disease characteristics and treatment effects, and, correlations with NHP and QOLIE-31 scores for convergent and divergent validity. Both acceptability and reproducibility were good and internal consistency was high (Cronbach's alpha coefficient = 0.92). Factor analysis with varimax rotation identified five factors: the first, related to cognitive function accounted for 26.0% of the variance. Discriminative validity was good for most treatment characteristics (tolerability, seizure control, compliance) and clinical features (epilepsy type, seizure frequency and severity, depressive symptoms). Correlations with the NHP and QOLIE-31 scores were consistently strong. It was concluded that the psychometric properties of the French translation of SEALS were similar to the original English version. In addition, SEALS provides information on quality of life that is complementary to that obtained with QOLIE-31. In particular, with respect to the QOLIE-31, the SEALS provides information on cognitive and neuropsychological aspects of impairment of quality of life, whereas the QOLIE-31 has a broader scope, taking into account multiple aspects of quality of life in epilepsy.
Asunto(s)
Comparación Transcultural , Epilepsia/psicología , Satisfacción Personal , Calidad de Vida , Encuestas y Cuestionarios , Adolescente , Adulto , Análisis Factorial , Femenino , Francia , Humanos , Lenguaje , Masculino , Persona de Mediana Edad , Psicometría , Reproducibilidad de los ResultadosRESUMEN
The prevalence of nasal polyposis (NP) in France (2.11 per cent) and its epidemiology (detection, medical management, patients' characteristics, risk factors, associated diseases, etc.) were determined in a population-based, cross-sectional, case-control study of 10 033 adults carried out in 2002. The impact of this disease on daily living was also studied, by the analysis of potential sleep disorders (validated questionnaire) and quality of life (QOL, SF-36 questionnaire) of NP patients, in a comparison with a matched-control group of individuals without NP. A quarter of NP patients (24.6 per cent) reported a feeling of general discomfort due to their nasal condition, during the day as well as the night in most of these cases (61.2 per cent). Compared with controls, NP patients have a two-fold higher risk of suffering sleep disturbance (odds ratio [OR]: 2.25, 95 per cent confidence interval [95% CI] [1.54; 3.29]). Snoring was reported by 50.5 per cent of NP patients vs 35.7 per cent of controls (p < 0.001). All scores from the SF-36 questionnaire demonstrated a significant negative impact of NP on the different aspects of QOL. The current study underlines the negative impact of NP on QOL and sleep, two dimensions that are rarely considered in its pathology. In addition to the discomfort and lowered QOL experienced by patients with this disease, a significant increase in sleep disorders was shown, suggesting a risk of suffering further chronic diseases and complications.